ClinicalTrials.Veeva

Menu

Iloprost Therapy in Patients With Critical Limb Ischemia

Bayer logo

Bayer

Status

Completed

Conditions

Peripheral Arterial Disease

Treatments

Drug: Iloprost (Ilomedin, BAYQ6256)

Study type

Observational

Funder types

Industry

Identifiers

NCT01458041
15439
VE1011HU (Other Identifier)

Details and patient eligibility

About

Monitoring efficacy and safety aspects of iv. iloprost therapy of patients with critical limb ischemia by recording clinical parameters.

Enrollment

126 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who fulfill the internationally defined criteria of critical limb ischemia;
  • Patients who are not eligible for vascular surgery or angioplasty interventions and
  • Patients who are treated with iloprost infusion.
  • The treating physician has decided iloprost treatment before study enrollment.

Exclusion criteria

  • Exclusion criteria are in accordance with the Summary of Product Characteristics of Ilomedin.

Trial design

126 participants in 1 patient group

Group 1
Treatment:
Drug: Iloprost (Ilomedin, BAYQ6256)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems